论文部分内容阅读
目的分析紫杉醇联合顺铂新辅助化疗在局部晚期宫颈癌中的应用价值。方法选取102例局部晚期宫颈癌患者随机分为治疗组和对照组,治疗组患者给予紫杉醇联合顺铂新辅助化疗后手术治疗,对照组患者仅给予手术治疗,比较两组患者临床疗效。结果治疗组患者临床疗效CR率+PR率为84.31%,优于对照组患者的41.18%,治疗组患者阴道切缘阳性率、淋巴结阳性率、宫旁累及率、脉管浸润率较对照组患者均显著下降,治疗组患者消化道、骨髓抑制Ⅰ,Ⅱ反应较对照组患者显著提高,差异均具有统计学意义(P<0.05)。结论紫杉醇联合顺铂新辅助化疗能够提高局部晚期宫颈癌的临床疗效,降低术后阴道切缘阳性率、淋巴结阳性率、宫旁累及率、脉管浸润率,毒副反应在可耐受范围内。
Objective To analyze the value of neoadjuvant chemotherapy with paclitaxel plus cisplatin in locally advanced cervical cancer. Methods A total of 102 patients with locally advanced cervical cancer were randomly divided into treatment group and control group. The patients in the treatment group were given paclitaxel and cisplatin combined with neoadjuvant chemotherapy. The patients in the control group were given only surgical treatment. The clinical efficacy was compared between the two groups. Results The CR rate + PR rate in the treatment group was 84.31%, which was higher than that in the control group (41.18%). The positive rate of vaginal margins, lymph node positive rate, paracancerous involvement rate and vascular infiltration rate in the treatment group were significantly higher than those in the control group Were significantly decreased, the treatment group patients with digestive tract, bone marrow suppression Ⅰ, Ⅱ response than the control group were significantly increased, the differences were statistically significant (P <0.05). Conclusions Neoadjuvant chemotherapy with paclitaxel combined with cisplatin can improve the clinical efficacy of locally advanced cervical cancer and reduce the positive rate of vaginal margins, lymph node positive rate, uterine paracancerous rate, vascular invasion rate and toxic side effects within the tolerable range .